Evidence map›Paper›PMID 40777863›Full record

ArticleEClinicalMedicine2025

Time-to-pregnancy in patients with previous breast cancer and unexposed women: a prospective exposed-unexposed cohort study.

Anne-Sophie Hamy, Agathe Chabassier, Clara Sebbag, Christine Rousset-Jablonski, Clémentine Berkach, Isabelle Ray-Coquard, Laura Sablone, Lauren Darrigues, Elise Dumas, Angélique Bobrie and 21 more

Abstract read
In one paragraph

Article in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Anne-Sophie HamyDepartment of Medical Oncology, Institut Curie, Paris, France.
Agathe ChabassierResidual Tumor and Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Université Paris Cité, Paris, France.
Clara SebbagDepartment of Medical Oncology, Institut Curie, Paris, France.
Christine Rousset-JablonskiCentre Léon Bérard, Lyon, France.
Clémentine BerkachUnité de Génétique Clinique, Hôpital Saint-Louis, APHP, France.
Isabelle Ray-CoquardCentre Léon Bérard, Lyon, France.
Laura SabloneSeintinelles Research Network, 40 Rue Rémy Dumoncel, Paris, 75014, France.
Lauren DarriguesDepartment of Surgical Oncology, Institut Curie, Paris, France.
Elise DumasResidual Tumor and Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Université Paris Cité, Paris, France.
Angélique BobrieDepartment of Medical Oncology, Institut du Cancer de Montpellier, Université de Montpellier, INSERM Unité 1194, Montpellier, France.
William JacotDepartment of Medical Oncology, Institut du Cancer de Montpellier, Université de Montpellier, INSERM Unité 1194, Montpellier, France.
Marc EspiéSénopole, Hôpital Saint-Louis, AP-HP, Paris, France.
Sylvie GiacchettiSénopole, Hôpital Saint-Louis, AP-HP, Paris, France.
Floriane JochumResidual Tumor and Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Université Paris Cité, Paris, France.
Aullène ToussaintDepartment of Medical Oncology, Institut Curie, Paris, France.
Geneviève Plu-BureauDepartment of Gynecology, Hôpital Cochin, Paris, France.
Lorraine Maitrot-ManteletDepartment of Gynecology, Hôpital Cochin, Paris, France.
Anne GompelDepartment of Gynecology, Hôpital Cochin, Paris, France.
Paul GougisResidual Tumor and Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Université Paris Cité, Paris, France.
Raphaëlle BasDepartment of Medical Oncology, Institut Curie, Paris, France.
Christine DecanterART Department, Centre Hospitalier Régional Lille, Lille, France.
Bernard AsselainDepartment of Biostatistics, Unicancer, Paris, France.
Charles CoutantClinical Research Department, Centre Georges-François Leclerc (Unicancer), Dijon, France.
Lili SohnSeintinelles Research Network, 40 Rue Rémy Dumoncel, Paris, 75014, France.
Guillemette JacobSeintinelles Research Network, 40 Rue Rémy Dumoncel, Paris, 75014, France.
Claire SauleDepartment of Medical Oncology, Institut Curie, Paris, France.
Sophie FrankDepartment of Medical Oncology, Institut Curie, Paris, France.
Judith AbécassisProject-team Soda, Inria Saclay, Palaiseau, France.
Florence CoussyDepartment of Medical Oncology, Institut Curie, Paris, France.
Fabien ReyalResidual Tumor and Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Université Paris Cité, Paris, France.
Seintinelles Research Network

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Data on fertility after breast cancer (BC) relative to the general population are lacking. This study aimed to compare the time-to-pregnancy between women with and without prior BC seeking to become pregnant. Methods: We conducted a prospective exposed-unexposed cohort study between March 13, 2018 and June 27, 2019, recruiting participants via the collaborative network Seintinelles. Women aged 18-43 years with a history of localized BC without relapse (exposed) were compared to women without BC (unexposed). Follow-up data were collected every six months over three years. The primary endpoint, time-to-pregnancy, was analyzed using Kaplan-Meier survival analysis with inverse probability weighting. Censoring was performed if women stopped trying to conceive for personal reasons, were lost to follow-up before conception, or completed the study without achieving pregnancy or using assisted reproductive technologies (ART). Findings: Among 4351 women enrolled, 642 sought pregnancy during the study period (76 exposed, 566 unexposed). Among them, 50 exposed (65.8%) and 402 weighted unexposed women (weighted percentage 71.0%) became pregnant at least once. Median time-to-pregnancy was 5.0 months, 95% CI [3.0-7.0] for exposed and 3.0 months, 95% CI [2.0-5.0] for unexposed women (difference in median time-to-pregnancy: 2.0 months, 95% CI [-2.5; 5]). Two years after starting to seek pregnancy, 74.9% of weighted unexposed women and 74.1% of exposed women obtained a pregnancy. Overall, 15 exposed women (19.8%) used either ART methods ( Interpretation: In this study from a French collaborative research network, we found no strong evidence of a largely reduced time-to-pregnancy in exposed women seeking to become pregnant compared with unexposed women. Further research on fertility outcomes in the broader population of BC survivors is warranted. Funding: The FEERIC study was funded by

Indexed as

Breast cancerInfertilityPregnancySurvivorsTime-to-pregnancy

Identifiers

PMID40777863
PMCPMC12329507

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.